• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prostate-specific Antigen Velocity Risk Count to Discern Significant From Indolent Prostate Cancer.

作者信息

Lundon Dara, Loeb Stacy

机构信息

Department of Urology, New York University, New York.

Department of Urology and Population Health, New York University and the Manhattan Veterans Affairs Medical Center, New York, NY.

出版信息

Rev Urol. 2014;16(3):154-6.

PMID:25337050
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4191640/
Abstract
摘要

相似文献

1
Prostate-specific Antigen Velocity Risk Count to Discern Significant From Indolent Prostate Cancer.前列腺特异性抗原速度风险计数以区分侵袭性前列腺癌与惰性前列腺癌。
Rev Urol. 2014;16(3):154-6.
2
Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer.前列腺特异性抗原速度风险计数可预测低风险前列腺癌患者的活检再分类。
J Urol. 2014 Mar;191(3):629-37. doi: 10.1016/j.juro.2013.09.029. Epub 2013 Sep 20.
3
Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).在前列腺癌筛查中，前列腺特异性抗原速度对临床显著前列腺癌具有特异性吗？欧洲前列腺癌筛查随机研究（鹿特丹）。
Eur Urol. 2009 Feb;55(2):385-92. doi: 10.1016/j.eururo.2008.02.046. Epub 2008 Mar 11.
4
Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.前列腺特异性抗原速度（PSAV）风险计数可提高临床显著前列腺癌筛查的特异性。
BJU Int. 2012 Feb;109(4):508-13; discussion 513-4. doi: 10.1111/j.1464-410X.2011.10900.x. Epub 2012 Feb 1.
5
Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations.用于预测惰性前列腺癌的列线图：对筛查发现人群的影响。
Cancer. 2007 Nov 15;110(10):2218-21. doi: 10.1002/cncr.23029.
6
Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer.前列腺癌筛查患者与转诊患者的前列腺特异性抗原速度比较。
J Urol. 2008 Apr;179(4):1340-3. doi: 10.1016/j.juro.2007.11.068. Epub 2008 Mar 4.
7
Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.诊断前前列腺特异性抗原速度与近距离放射治疗和外照射放疗后前列腺癌进展风险相关。
J Urol. 2006 Oct;176(4 Pt 1):1399-403. doi: 10.1016/j.juro.2006.06.045.
8
Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.前列腺特异性抗原速度并不能帮助以前活检阴性的男性检测前列腺癌。
J Urol. 2010 Sep;184(3):907-12. doi: 10.1016/j.juro.2010.05.029.
9
Revised Gleason grading system is a better predictor of indolent prostate cancer at the time of diagnosis: retrospective clinical-pathological study on matched biopsy and radical prostatectomy specimens.修订后的Gleason分级系统在诊断时能更好地预测惰性前列腺癌：对匹配的活检和根治性前列腺切除术标本的回顾性临床病理研究
Clin Genitourin Cancer. 2014 Oct;12(5):325-9. doi: 10.1016/j.clgc.2014.01.009. Epub 2014 Feb 4.
10
Who bears the greatest burden of aggressive treatment of indolent prostate cancer?惰性前列腺癌积极治疗的最大负担由谁承担？
Am J Med. 2015 Jun;128(6):609-16. doi: 10.1016/j.amjmed.2014.12.030. Epub 2015 Jan 30.

本文引用的文献

1
Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer.前列腺特异性抗原速度风险计数可预测低风险前列腺癌患者的活检再分类。
J Urol. 2014 Mar;191(3):629-37. doi: 10.1016/j.juro.2013.09.029. Epub 2013 Sep 20.
2
Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.前列腺特异性抗原速度（PSAV）风险计数可提高临床显著前列腺癌筛查的特异性。
BJU Int. 2012 Feb;109(4):508-13; discussion 513-4. doi: 10.1111/j.1464-410X.2011.10900.x. Epub 2012 Feb 1.
3
Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.对前列腺特异性抗原预处理速度和倍增时间作为前列腺癌预测指标的系统评价。
J Clin Oncol. 2009 Jan 20;27(3):398-403. doi: 10.1200/JCO.2008.18.1685. Epub 2008 Dec 8.
4
Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).在前列腺癌筛查中，前列腺特异性抗原速度对临床显著前列腺癌具有特异性吗？欧洲前列腺癌筛查随机研究（鹿特丹）。
Eur Urol. 2009 Feb;55(2):385-92. doi: 10.1016/j.eururo.2008.02.046. Epub 2008 Mar 11.
5
Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability.前列腺特异性抗原速度风险计数评估：一种在可治愈窗口期检测危及生命的前列腺癌的新概念。
Urology. 2007 Oct;70(4):685-90. doi: 10.1016/j.urology.2007.05.010.
6
Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.主动监测：前列腺癌患者合理的治疗选择：迈阿密经验
BJU Int. 2008 Jan;101(2):165-9. doi: 10.1111/j.1464-410X.2007.07190.x. Epub 2007 Sep 10.
7
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.在可治愈窗口期利用前列腺特异性抗原速度检测危及生命的前列腺癌。
J Natl Cancer Inst. 2006 Nov 1;98(21):1521-7. doi: 10.1093/jnci/djj410.
8
Active surveillance with selective delayed intervention for favorable risk prostate cancer.对低风险前列腺癌进行主动监测并选择性延迟干预。
Urol Oncol. 2006 Jan-Feb;24(1):46-50. doi: 10.1016/j.urolonc.2005.07.002.
9
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.术前前列腺特异抗原（PSA）变化率与根治性前列腺切除术后前列腺癌死亡风险
N Engl J Med. 2004 Jul 8;351(2):125-35. doi: 10.1056/NEJMoa032975.
10
Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection.
J Urol. 1994 Oct;152(4):1163-7. doi: 10.1016/s0022-5347(17)32528-4.